TRV GP IV’s Relay Therapeutics RLAY Stock Holding History

TRV GP IV’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,811,197	Closed	-$117M	–	5
2020 Q4	$117M	Hold	2,811,197	–	–	37.48%	1
2020 Q3	$120M	Buy	+2,811,197	New	+$107M	41.22%	1

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

TRV GP IV's RLAY Position: Q1 2021 in Review

TRV GP IV sold out of Relay Therapeutics (RLAY) in Q1 2021, closing a stake of 2,811,197 shares — an estimated $117M sold.

TRV GP IV first reported a position in RLAY in Q3 2020 and held it in 2 quarters. The position peaked at $120M in Q3 2020. 137 funds tracked by Wall St. Rank hold RLAY as of Q1 2021.

TRV GP IV reported no remaining Relay Therapeutics position as of Q1 2021 after selling out during the quarter.
TRV GP IV sold 2,811,197 Relay Therapeutics shares in Q1 2021, an estimated $117M.
TRV GP IV first reported a position in Relay Therapeutics in Q3 2020 and held it in 2 quarters.
TRV GP IV's Relay Therapeutics position peaked at $120M in Q3 2020.
137 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2021.

Based on TRV GP IV's 13F filing for Q1 2021, filed 12 May 2021.